Biostax Corp.
BTAX
$0.0002
$0.000.00%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -3.52% | -7.78% | -14.54% | -16.69% | -9.34% |
| Depreciation & Amortization | -65.67% | 1.49% | 202.99% | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -33.52% | -20.81% | -2.55% | 27.62% | 40.23% |
| Operating Income | 33.52% | 20.81% | 2.55% | -27.62% | -40.23% |
| Income Before Tax | -16.80% | 40.22% | -63.63% | 33.19% | 54.13% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.80% | 40.22% | -63.63% | 33.19% | 54.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.80% | 40.22% | -63.63% | 33.19% | 54.13% |
| EBIT | 33.52% | 20.81% | 2.55% | -27.62% | -40.23% |
| EBITDA | 20.36% | -42.33% | -233.16% | -- | -684.06% |
| EPS Basic | -15.10% | 52.86% | -101.09% | 98.97% | 99.40% |
| Normalized Basic EPS | 26.05% | 15.56% | -100.47% | -100.57% | -100.61% |
| EPS Diluted | -14.41% | 48.18% | -117.43% | 99.37% | 99.57% |
| Normalized Diluted EPS | 26.05% | 15.56% | -105.45% | 90.35% | 96.85% |
| Average Basic Shares Outstanding | 0.55% | 7.89% | 46.92% | 130.74% | 439.24% |
| Average Diluted Shares Outstanding | 1.17% | 8.56% | 43.35% | 119.92% | 383.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |